Dual-Agent Eye Drop for Presbyopia - Summary - MDSpire
FDA & Government News

Dual-Agent Eye Drop for Presbyopia

YUVEZZI™ approved for the treatment of presbyopia, blurry close-up vision due to aging

  • April 20, 2026

  • 2 min

Share

YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% has been launched by Tenpoint Therapeutics, Ltd. in the U.S. as a treatment for presbyopia, a condition affecting about 128 million adults in the country. This unique eye drop, designed for once-daily use, is now available through local retail pharmacies and an e-pharmacy partner, PHILRx. It combines two active ingredients for effective near vision improvement, addressing the needs of those experiencing age-related vision decline. The product is backed by eye care professionals to ensure its efficacy and safety.

Original Source(s)

Dual-Agent Eye Drop for Presbyopia

  • April 20, 2026

Related Content

Closing Communication Gaps in Eye Care

Study findings highlight communication barriers in ophthalmology and outline a structured framework designed to support understanding, expectation-setting, and adherence.

Integrating EyeCare

As demand for ophthalmic services surges, EyeCare Partners is building a physician-led network designed to meet rising clinical and research needs

  • April 20, 2026

  • 10 min
Introducing: Moorfields and UCL Centre for Eye Health

New London eye health centre named ahead of 2027 summer opening

  • April 17, 2026

  • 2 min